Rocket Pharmaceuticals gets FDA RMAT status for heart disorder therapy

2 days ago 1
Double exposure microscope Young woman scientific using equipment for research. Genetic research and Biotech science Concept. Human Biology and pharmaceutical technology

jittawit.21/iStock via Getty Images

  • Rocket Pharmaceuticals (NASDAQ:RCKT) said that the U.S. FDA has given regenerative medicine advanced therapy (RMAT) status to their gene therapy, RP-A601, for treating a heart condition known as PKP2-arrhythmogenic cardiomyopathy.
  • The stock is up 14% premarket.
  • The RMAT allows the

Recommended For You

More Trending News

Read Entire Article